The complete side effect frequency breakdown from Phase 2 trials: Very Common (20%+ of patients at 12mg dose) Nausea: 28% Typically mild to moderate, peaks weeks 4-8, usually resolves by week 12 Diarrhea: 24% Usually transient (1-3 weeks), rarely severe Constipation: 21% Paradoxically coexists with diarrhea in different patients Common (10-20% of patients) Vomiting: 17% Decreased appetite: 16% (beyond therapeutic effect) Injection site reactions: 14% Fatigue: 13% Dyspepsia (indigestion): 12% Headache: 11% Uncommon (2-10% of patients) Abdominal pain: 8% Dizziness: 7% Gastroesophageal reflux: 6% Hypoglycemia in diabetics on other medications: 5% Increased heart rate (average 2-4 bpm): 4% Hair thinning/loss: 3% (typically temporary) Rare but Serious (Under 2%) Pancreatitis: 0.3% (3 cases out of 1,032 patients, all resolved with discontinuation) Gallbladder events: 1.4% (expected with rapid weight loss regardless of method) Acute kidney injury: 0.7% (all cases associated with severe dehydration) KEY TAKEAWAY: About 30% experience meaningful nausea in the first 4-8 weeks
It is about choosing the right tool for the actual condition
Pen Dosage Chart GLP-2T 5-Amino-1MQ Slu-pp-332 Capsules Dosage & Protocols Variations GLP-2T Standard Research Protocol Dose: 2.5 5 mg (variant 5 mg pen = 76152 clicks / variant 10 mg pen = 2550 clicks / variant 15 mg pen = 2550 clicks) Duration: 8 12 weeks Frequency: 1 weekly Cycle Interval: Optional 2-week pause Goal / Description: For basic metabolic modulation studies Therapeutic Research Protocol Dose: 10 15 mg (variant 15 mg pen = 100150 clicks) Duration: 24 48 weeks Frequency: 1 weekly Cycle Interval: Repeat after 1 month Goal / Description: Modeled on SURPASS/SURMOUNT designs
Express Shipping Available upon request at an additional charge
Methylcobalamin tablets are used to treat vitamin B12 deficiency, support nerve health, manage mild to moderate neuropathy, and provide nutritional supplementation
